Weekend ICYMI: September 9 to September 13
Drug Topics
SEPTEMBER 15, 2024
In case you missed it, this week we had news about novel treatments for dry eye disease, art therapy and mental health, abdominal fat's role in pain, and more.
Sun.Sep 15, 2024
216 
STAT+: Exact Sciences reports initial positive results in colon cancer blood test, but pivot trial still pending
STAT
SEPTEMBER 15, 2024
Exact Sciences, which has for years sold a stool-based colon cancer test, on Monday announced that a blood-based test it’s developing showed promise in accurately detecting the disease. In a study of more than 3,000 samples, the company reported that its test detected 88.3% of cancers and correctly returned a negative result 90.1% of the time, test features known as sensitivity and specificity, respectively.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
ESMO: GSK, iTeos bring some optimism back to TIGIT
pharmaphorum
SEPTEMBER 15, 2024
GSK, iTeos TIGIT drug belrestotug shows efficacy in PD-L1-high NSCLC trial at ESMO, giving some positive news for the beleaguered class
STAT+: AstraZeneca’s Imfinzi increases survival rates in bladder cancer in pivotal study
STAT
SEPTEMBER 15, 2024
BARCELONA, Spain — An AstraZeneca immunotherapy, given both before and after surgery, improved survival rates in patients with bladder cancer, results that could reshape how muscle-invasive bladder tumors are treated. The regimen using Imfinzi, the company’s anti-PD-L1 checkpoint inhibitor, cut the risk of death by 25% compared to treating patients before surgery with chemotherapy alone, researchers reported Sunday.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
ESMO: Enhertu shows its worth in brain metastases
pharmaphorum
SEPTEMBER 15, 2024
Women with HER2-positive breast cancer can be treated with AstraZeneca and Daiichi Sankyo's Enhertu, regardless of whether their cancer has spread to the brain, according to a new study.The results of the open-label DESTINY-Breast12 trial – reported at the ESMO cancer congress in Barcelona – showed that nearly two-thirds (61.6%) of patients with brain metastases at baseline who were treated with the HER2-directed antibody-drug conjugate (ADC) were alive without disease progression at one year.
Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Is New Standard of Care for High-Risk Early-Stage TNBC
Pharmacy Times
SEPTEMBER 15, 2024
Overall survival results from the phase 3 KEYNOTE-522 study provide evidence of improved long-term outcomes from this pembrolizumab-based regimen.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
Top 5 Drugs That Cause Insomnia
Med Ed 101
SEPTEMBER 15, 2024
Many drugs cause insomnia. What is most frustrating to me in my practice is when we start medications for a “new condition” prior to ruling out medication adverse effects. Here is the list of my top 5 drugs that cause insomnia (an important adverse effect that could show up on your board exam). Corticosteroids. They […] The post Top 5 Drugs That Cause Insomnia appeared first on Med Ed 101.
ESMO 2024: Enhertu to eclipse SOC for HER2+ breast cancer with brain metastases
Pharmaceutical Technology
SEPTEMBER 15, 2024
GlobalData forecasts predict Enhertu will retain its dominant market position in the ADC treatment landscape.
The Greatest Trick the Devil Ever Pulled was Convincing the World He Didn’t Exist: Senate Judiciary Set to Mark-Up Patent Reform Bills that Could Significantly Affect Hatch-Waxman and the BPCIA
The FDA Law Blog
SEPTEMBER 15, 2024
By Kurt R. Karst — “Inter Partes Review” and “Section 101” are not terms you typically run into on this all-things-FDA blog, but we have talked about such patent-related issues before ( here and here ), and they are important legal (patent) principles, particularly in the context of drug and biological products (and the Hatch-Waxman Amendments and the Biologics Price Competition and Innovation Act (“BPCIA”)).
Advances in the Treatment of Resectable NSCLC: Key Insights From CheckMate 77T, NEOSTAR, and CA209-159 Trials
Pharmacy Times
SEPTEMBER 15, 2024
Clinical research presented at ESMO 2024 highlights the significant survival benefits of perioperative and neoadjuvant immunotherapy with nivolumab and nivolumab plus ipilimumab, while emphasizing the role of biomarkers such as ctDNA and KRAS mutations in guiding treatment decisions.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
ESMO: Bayer hopes to expand Nubeqa's prostate cancer reach with chemo-free regimen
Fierce Pharma
SEPTEMBER 15, 2024
Bayer is targeting a broader use of Nubeqa in metastatic hormone-sensitive prostate (mHSPC) cancer with a combination free of chemotherapy. | Bayer is targeting a broader use of Nubeqa in metastatic hormone-sensitive prostate cancer with a combination free of chemotherapy.
It’s Fall Prevention Awareness Week
OctariusRx
SEPTEMBER 15, 2024
It’s Fall Prevention Awareness Week and the OctariusRx team is recognizing and helping to spread the word on behalf of the National Council on Aging (NCOA). There are many factors that impact our risk of falls, but it’s important to remember that falling is NOT a normal part of aging. Join us the week of Sept. 16-20 in a nationwide effort to prevent falls among older adults.
Is Retail Pharmacy Right For You?
The Happy PharmD
SEPTEMBER 15, 2024
Retail pharmacy careers have long been a hot topic among pharmacists, and for good reason. These roles make up nearly half of all pharmacy jobs in the U.S., operating within a network of thousands of pharmacies across the country. Despite the sheer volume of prescriptions processed — over 4 billion annually — the landscape of retail pharmacy has undergone significant scrutiny in recent years.
ESMO 2024: TIGIT race tightens with first look at GSK/iTeos’s TIGIT in NSCLC
Pharmaceutical Technology
SEPTEMBER 15, 2024
The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC treatment paradigm.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Is Retail Pharmacy Right For You?
The Happy PharmD
SEPTEMBER 15, 2024
Retail pharmacy careers have long been a hot topic among pharmacists, and for good reason. These roles make up nearly half of all pharmacy jobs in the U.S., operating within a network of thousands of pharmacies across the country. Despite the sheer volume of prescriptions processed — over 4 billion annually — the landscape of retail pharmacy has undergone significant scrutiny in recent years.
Can you take Dupixent while pregnant?
The Checkup by Singlecare
SEPTEMBER 15, 2024
Dupixent (dupilumab) is an injectable medication used to treat moderate-to-severe atopic dermatitis (AD), also known as eczema, in adults and children 6 years and older. It is also approved by the Food and Drug Administration (FDA) for several other uses, including: As an add-on maintenance treatment for severe asthma in adults and children 6 years and older As an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps in adults As a treatment for prurigo nodularis in adults A
State of Well-Being 2023-2024
The Happy PharmD
SEPTEMBER 15, 2024
Wondering how our healthcare professionals, especially pharmacists, are faring lately? Well, now’s the perfect time to dive into a discussion with me about the latest insights from the 2023 report by the Well-Being Index. Whether you’re new here or a regular viewer, a warm welcome awaits you! And if you’re eager to stay updated with insightful content, don’t forget to hit that subscribe button and notification bell.
Let's personalize your content